Venture Capital
SAN CARLOS, Calif., Aug. 8, 2018 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million. The $15 million Series B financing was led by Decheng...

In this article